LeonaBio
Develops lasofoxifene for metastatic breast cancer and ATH-1105 for ALS.
$7.83
After-hours close−0.17 (−2.12%)
At close$8.00(+1.39%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 11.74%
Shares outstanding 3.94M · Float 2.68M · 68.0% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. +1 more | 19.99% | 1.89M | 13D | Aug 25, 2026 ↗ |
| ADAR1 Capital Management, LLC | 7.70% | 727.5K | 13G | May 15, 2026 ↗ |
| Steven Michael Oliveira | 5.11% | 13G | Apr 16, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | director, 10 percent owner: | 329.8K | 8.36% | Dec 23, 2025 |
| Mark James Litton | director, officer: PRESIDENT and CEO | 57.9K | 1.47% | Mar 5, 2026 |
| Kevin Church | officer: CHIEF SCIENTIFIC OFFICER | 25.2K | 0.64% | Mar 5, 2026 |
| Mark Worthington | officer: GENERAL COUNSEL and CCO | 18.4K | 0.47% | Mar 5, 2026 |
| Martin Javier San | officer: CHIEF MEDICAL OFFICER | 15.9K | 0.40% | Mar 5, 2026 |
| Robert Renninger | officer: CHIEF FINANCIAL OFFICER | 15.9K | 0.40% | Mar 5, 2026 |
1 ten-percent owner holds 191.9K shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only · 10 people have not refiled in the last 18 months (444.6K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 4, 2026 | Martin Javier Sanofficer: CHIEF MEDICAL OFFICER | Sale | 1,720 | $5.37 | 15,887 |
| Mar 4, 2026 | Kevin Churchofficer: CHIEF SCIENTIFIC OFFICER | Sale | 1,359 | $5.37 | 25,178 |
| Mar 4, 2026 | Mark Worthingtonofficer: GENERAL COUNSEL and CCO | Sale | 1,328 | $5.37 | 18,376 |
| Mar 4, 2026 | Robert Renningerofficer: CHIEF FINANCIAL OFFICER | Sale | 906 | $5.37 | 15,851 |
| Mar 4, 2026 | Mark James Littondirector, officer: PRESIDENT and CEO | Sale | 5,156 | $5.37 | 57,926 |
| Jan 2, 2026 | Mark Worthingtonofficer: General Counsel and CCO | Sale | 876 | $6.88 | 13,978 |
| Jan 2, 2026 | Kevin Churchofficer: CHIEF SCIENTIFIC OFFICER | Sale | 876 | $6.88 | 20,681 |
| Jan 2, 2026 | Robert Renningerofficer: Chief Financial Officer | Sale | 297 | $6.88 | 12,857 |
| Jan 2, 2026 | Mark James Littondirector, officer: President and CEO | Sale | 2,586 | $6.88 | 40,828 |
| Jan 2, 2026 | Martin Javier Sanofficer: CHIEF MEDICAL OFFICER | Sale | 1,644 | $6.88 | 10,189 |
CongressHouse and Senate disclosures
Not reported.